🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

173+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 173 recruiting trials for “squamous-cell-carcinoma-of-the-hypopharynx

Phase 2RecruitingNCT07266493

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

🏥 Shanghai Zhongshan Hospital📍 1 site📅 Started Dec 2023View details ↗
RecruitingNCT06169163

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

🏥 Imperial College London📍 13 sites📅 Started Dec 2023View details ↗
NARecruitingNCT06017895

Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma

👨‍⚕️ Jian Guan, MD, Nanfang Hospital, Southern Medical University📍 1 site📅 Started Oct 2023View details ↗
Phase 2RecruitingNCT06190639

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

🏥 Zhejiang Cancer Hospital📍 1 site📅 Started Oct 2023View details ↗
NARecruitingNCT06167109

NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma

👨‍⚕️ Ying Wang, Ph.D, M.D., Chongqing University Cancer Hospital📍 1 site📅 Started Oct 2023View details ↗
Phase 3RecruitingNCT06022861

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

🏥 Shandong Boan Biotechnology Co., Ltd📍 1 site📅 Started Oct 2023View details ↗
Phase 3RecruitingNCT06092957

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

👨‍⚕️ Ming-Yuan Chen, MD,PhD, Sun Yat-sen University📍 1 site📅 Started Oct 2023View details ↗
Phase 2RecruitingNCT06061146

Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

👨‍⚕️ Wencheng Zhang, M.D, Tian jin cancer hospital📍 1 site📅 Started Oct 2023View details ↗
Phase 2RecruitingNCT06055816

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

👨‍⚕️ Xiaozhong Chen, Department of Radiation Oncology, Zhejiang Cancer Hospital📍 1 site📅 Started Sep 2023View details ↗
Phase 2RecruitingNCT06056336

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

👨‍⚕️ Changqing Pan, the International Committee of Medical Journal Editors📍 1 site📅 Started Sep 2023View details ↗
Phase 2RecruitingNCT06603402

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

👨‍⚕️ zhenyu ding, MD, West China Hospital, Sichuan University, China📍 1 site📅 Started Aug 2023View details ↗
Phase 3RecruitingNCT05780372

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

👨‍⚕️ Chong Zhao, MD PhD, Sun Yat-sen University📍 7 sites📅 Started Aug 2023View details ↗
Phase 1RecruitingNCT05984342

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

🏥 Affiliated Cancer Hospital of Shantou University Medical College📍 1 site📅 Started Aug 2023View details ↗
Phase 1, PHASE2RecruitingNCT05473156

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

🏥 AP Biosciences Inc.📍 1 site📅 Started Jul 2023View details ↗
Phase 1RecruitingNCT06886347

Metastatic Nasopharyngeal Carcinoma

🏥 Chen Xiaozhong📍 1 site📅 Started Jul 2023View details ↗
Phase 2RecruitingNCT06186609

PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC

👨‍⚕️ Yu Weiwei, Department of Radiation Oncology, Affiliated Hospital of Nantong University📍 1 site📅 Started Jul 2023View details ↗
RecruitingNCT05833594

Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma

🏥 Anhui Provincial Hospital📍 1 site📅 Started Jul 2023View details ↗
Phase 3RecruitingNCT05919030

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

🏥 Renmin Hospital of Wuhan University📍 1 site📅 Started Jul 2023View details ↗
Phase 1, PHASE2RecruitingNCT05319730

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

👨‍⚕️ Medical Director, Merck Sharp & Dohme LLC📍 57 sites📅 Started May 2023View details ↗
RecruitingNCT05894369

Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

🏥 Renmin Hospital of Wuhan University📍 1 site📅 Started May 2023View details ↗
← PreviousPage 6 of 9Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →